玛伐凯泰(Mavacamten) - 药物靶点：Cardiac myosin_在研适应症：梗阻性肥厚型心肌病，非梗阻性肥厚型心肌病，射血分数保留型心力衰竭_专利_临床

概要

基本信息

药物类型

小分子化药

别名

MAVA、MAVA-Myokardia

+ [8]

靶点

Cardiac myosin

作用方式

抑制剂

作用机制

心肌肌球蛋白复合体抑制剂

治疗领域

心血管疾病

在研适应症

梗阻性肥厚型心肌病非梗阻性肥厚型心肌病射血分数保留型心力衰竭+ [1]

非在研适应症-

原研机构

Bristol Myers Squibb Co.

在研机构

Bristol Myers Squibb Co.Bristol-Myers Squibb Pharma EEIGBMS Korea Co. Ltd.

+ [4]

非在研机构-

权益机构

LianBio

Sanofi

MyoKardia, Inc.

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (2022-04-28),

梗阻性肥厚型心肌病

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C15H19N3O2

InChIKeyRLCLASQCAPXVLM-NSHDSACASA-N

CAS号1642288-47-8

关联

34

项与玛伐凯泰相关的临床试验

NCT06947590

/ Active, not recruitingN/AIIT

Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy: A Randomized Controlled Trial

This study aimed to evaluate the efficacy and safety of Mavacamten compared to no treatment in patients with symptomatic latent obstructive hypertrophic cardiomyopathy. The trial was randomized into two groups: Mavacamten group and Non-Mavacamten group. Over the 30-week treatment period, patients underwent a series of assessments at predefined time points, including transthoracic echocardiography, electrocardiogram (ECG), Holter monitoring, NYHA functional classification, Kansas City Cardiomyopathy Questionnaire (KCCQ), and cardiac biomarkers.

开始日期2025-04-20

申办/合作机构

上海市胸科医院

NCT06856265

/ Not yet recruitingN/AIIT

Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

This study aims to evaluate the efficacy and safety of Mavacamten combined with radiofrequency ablation compared to Mavacamten alone in patients with symptomatic obstructive hypertrophic cardiomyopathy (HOCM).
Participants were randomized into two groups:

开始日期2025-02-26

申办/合作机构

上海市胸科医院

NCT06146660

/ RecruitingN/A

CAMZYOS® (Mavacamten) Post-Marketing Surveillance in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.

开始日期2024-07-24

申办/合作机构

Bristol Myers Squibb Co.

100 项与玛伐凯泰相关的临床结果

登录后查看更多信息

100 项与玛伐凯泰相关的转化医学

登录后查看更多信息

100 项与玛伐凯泰相关的专利（医药）

登录后查看更多信息

359

项与玛伐凯泰相关的文献（医药）

2025-06-01·Current Problems in Cardiology

A Multidimensional Approach to Understanding Genetic Diversity, Risk Stratification, and Personalized Interventions in Pediatric Hypertrophic Cardiomyopathy

Review

作者: Alromaihi, Mona ; Alrumaihi, Faris ; Alwanian, Wanian M ; Alfifi, Somayah Mohammad ; Khan, Shahid Ullah ; Thornbury, William ; Alharbi, Hajed Obaid ; AlDuayji, Nouf Nasser ; Al-Doaiss, Amin A ; Alshabrmi, Fahad M

Hypertrophic cardiomyopathy (HCM) in children presents unique challenges distinct from adult manifestations, with potentially devastating consequences, including sudden cardiac death. This comprehensive review synthesizes current evidence on the pathophysiology, clinical presentation, and management of pediatric HCM, highlighting critical differences from adult populations. While affecting approximately 1 in 500 individuals, pediatric HCM demonstrates more significant etiological heterogeneity, with up to 35% of cases stemming from non-sarcomeric causes, including RASopathies, metabolic disorders, and syndromic conditions. This etiological diversity contributes to variable disease trajectories and treatment responses, creating a significant research gap in pediatric-specific management protocols. Current pharmacological approaches primarily employ beta-blockers as first-line therapy, with calcium channel blockers serving as alternatives for intolerant patients. However, these conventional medications manage symptoms without addressing underlying pathophysiology or preventing disease progression. Emerging investigational therapies, including angiotensin receptor blockers and myosin inhibitors like mavacamten, show promise in preliminary studies but lack robust pediatric-specific evidence. Surgical interventions, including septal myectomy and the modified Konno procedure, demonstrate efficacy in medication-refractory cases but carry higher complication risks in younger patients. The critical research gap lies in developing targeted therapeutic approaches for pediatric-specific HCM subtypes, particularly those associated with syndromic and metabolic disorders. Additionally, risk stratification models for sudden cardiac death prevention remain inadequately validated in pediatric populations. This review identifies the urgent need for pediatric-focused clinical trials investigating both conventional and novel therapies alongside the development of age-appropriate risk assessment tools to guide personalized management strategies for this vulnerable population.

2025-05-05·Journal of General Physiology

Myosin binding protein-C modulates loaded sarcomere shortening in rodent permeabilized cardiac myocytes

Article

作者: Davis, Daniel J. ; Veteto, Adam B. ; McDonald, Kerry S. ; Kalogeris, Theodore J. ; Hanft, Laurin M.

During the ejection phase of the cardiac cycle, left ventricular (LV) cardiac myocytes undergo loaded shortening and generate power. However, few studies have measured sarcomere shortening during loaded contractions. Here, we simultaneously monitored muscle length (ML) and sarcomere length (SL) during isotonic contractions in rodent permeabilized LV cardiac myocyte preparations. In permeabilized cardiac myocyte preparations from rats, we found that ML and SL traces were closely matched, as SL velocities were within ∼77% of ML velocities during half-maximal Ca2+ activations. We next tested whether cardiac myosin binding protein-C (cMyBP-C) regulates loaded shortening and power output by modulating cross-bridge availability. We characterized force–velocity and power–load relationships in wildtype (WT) and cMyBP-C deficient (Mybpc3−/−) mouse permeabilized cardiac myocyte preparations, at both the ML and SL level, before and after treatment with the small molecule myosin inhibitor, mavacamten. We found that SL traces closely matched ML traces in both WT and Mybpc3−/− cardiac myocytes. However, Mybpc3−/− cardiac myocytes exhibited disproportionately high sarcomere shortening velocities at high loads. Interestingly, in Mybpc3−/− cardiac myocytes, 0.5 µM mavacamten slowed SL-loaded shortening across the force–velocity curve and normalized SL shortening velocity at high loads. Overall, these results suggest that cMyBP-C moderates sarcomere-loaded shortening, especially at high loads, at least in part, by modulating cross-bridge availability.

2025-05-01·Journal of Cardiothoracic and Vascular Anesthesia

Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors

Review

作者: Crystal, George J ; Pagel, Paul S ; Freed, Julie K ; Hang, Dustin

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. The disease is characterized by asymmetric left ventricular (LV) remodeling with myocyte disarray and interstitial fibrosis, a hypercontractile state, dynamic subaortic obstruction of the LV outflow tract, impaired LV diastolic function, atrial and ventricular arrhythmias, and sudden cardiac death. HCM occurs as a result of pathological alterations in the cardiac myocyte's chemomechanical cycle, in which an enhanced rate of myosin-actin crossbridge formation and destabilization of the energy-conserving "super-relaxed off-actin state" of myosin play essential roles. For decades, management of HCM has been limited almost exclusively to medications (eg, beta-blockers, calcium channel blockers, disopyramide) and interventions (eg, septal reduction therapy, implanted cardioverter-defibrillator devices) that palliate symptoms, but do not address the disease's underlying causative mechanisms. A new class of cardiovascular medications, cardiac myosin inhibitors, has surged to the forefront of HCM treatment in recent years. These drugs, including mavacamten and aficamten, show great promise to profoundly affect the disease's clinical course. In this article, the authors review the molecular mechanisms of action of cardiac myosin inhibitors, discuss in detail the most recent data from mavacamten and aficamten clinical trials, describe future planned studies designed to address unanswered questions about their clinical utility in HCM phenotypes, and comment on their potential application to patients with other forms of heart failure with preserved ejection fraction. The possible anesthetic implications of mavacamten and aficamten are also discussed because it is highly likely that patients who are treated with these medications will begin to present for perioperative care with increasing regularity.

368

项与玛伐凯泰相关的新闻（医药）

2025-05-02

·FierceBiotech

FDA delays decision date on Cytokinetics\' heart drug to year-end in unusual safety program back-and-forth

Cytokinetics\' addition of a REMS plan constituted a \"major\" application amendment, triggering a three-month delay.\n To REMS, or not to REMS.That, apparently, was the question for Cytokinetics, which has seen any potential approval for its experimental heart drug delayed by an extra three months over an unusual safety program omission and addition. Aficamten, a cardiac myosin inhibitor, had been on the books with the FDA for a potential approval by (or before) Sept. 26 for obstructive hypertrophic cardiomyopathy.This disease, characterized by the blood flow from the heart being reduced by the thickening of the heart\'s muscular wall, already has an approved treatment on the market in the form of Bristol Myers Squibb’s cardiac myosin inhibitor Camzyos.Cytokinetics was hoping to get into this market that has seen Camyzos bring in just over $600 million last year, but, now, those hopes will be on hold a while longer.The whole issue revolves around REMS, the shorthand for the FDA\'s Risk Evaluation and Mitigation Strategy programs. REMS are typically demanded by the FDA for potentially risky drugs and are a common requirement for heart disease meds.In a twist of fate, BMS also had a similar FDA REMS delay back in 2021, but its medicine was ultimately approved in 2022.In the U.S., Camzyos can only be used via a REMS program because it can cause the heart to become too relaxed, increasing the risk of heart failure. In its statement released after-hours Thursday, May 1, Cytokinetics said it had submitted its new drug application with the FDA without a plan for REMS, seemingly with the agency’s blessing. But not so fast: The FDA has now looked over the application and in fact does want a REMS plan “based on the inherent characteristics of aficamten,\" the company explained. While Cytokinetics has now provided the plan, the addition has been regarded as a “Major Amendment to the NDA,” according to the biotech, thus adding a mandatory three months to the review. The drug\'s decision is now expected by Dec. 26.Analysts at Evercore ISI were perplexed, saying in a note to clients: “We didn’t see this one coming. The most surprising part to us is that [aficamten\'s] NDA was originally submitted without an accompanying REMS. Was that actually the FDA’s guidance to the company or some sort of miscommunication? We assume the former given that the application was accepted.”The analysts added, however, that “the REMS was not expected to be the main differentiator for [aficamten].\" Shares in the biotech were down around 10% premarket. “We remain confident in the distinct benefit-risk and pharmaceutic profile of aficamten and continue to expect a differentiated label and risk mitigation profile upon its potential approval by FDA,” said Robert Blum, Cytokinetics’ president and CEO, in the release.“We look forward to continuing our constructive engagement with the FDA regarding the NDA for aficamten.”

$FDA delays decision date on Cytokinetics\' heart drug to year-end in unusual safety program back-and-forth$

申请上市上市批准

2025-05-02

·EndPoints

Missing REMS delays Cytokinetics' heart drug PDUFA, stock drops

Cytokinetics said late Thursday that the PDUFA date for its heart disease therapy aficamten would be delayed by three months to Dec. 26. The lag would allow the FDA to review a major change to its marketing application, namely the submission of a drug safety program or REMS. The major surprise here is that the company did not include a REMS in its original NDA filing. Stifel analysts described the omission as “not at all the Street’s expectation.” Previously, Cytokinetics’ management had said it would propose a REMS package when it submitted the NDA, they wrote on a Thursday note. Cytokinetics’ stock $CYTK was down by as much as 12% premarket Friday as investors digested the arguably unnecessary delay. The company appeared to suggest that the FDA was OK with the initial lack of a REMS, saying that it previously had pre-NDA discussions with the agency that led to the REMS-free filing, which the FDA accepted. The agency subsequently demanded a safety program “based on the inherent characteristics of aficamten,” though no extra clinical trials are needed. The PDUFA delay comes as the biopharma sector is keeping a close eye on the FDA, concerned that cuts could impact approval timelines . Aficamten is intended to treat the rare heart muscle condition obstructive hypertrophic cardiomyopathy, and in its pivotal trial, the cardiac myosin inhibitor beat placebo at improving oxygen uptake as patients exercised. Importantly, on a cross-trial basis, aficamten looked better than the existing medication for the disease, Bristol Myers Squibb’s Camzyos. Bristol Myers included a REMS program in its original NDA filing for Camzyos. That drug too had its approval date pushed back, from January to April 2022, to allow the FDA to assess updates to the proposed safety measures. In mid-April, the label of BMS’ drug was updated to lessen the REMS requirements, cutting the frequency of heart echo monitoring from every three to every six months, and lifting a ban on patients taking certain other drugs. Cytokinetics believes that aficamten will end up with differentiated REMS requirements to Camzyos, with even fewer restrictions.

申请上市

2025-04-28

·GBIHealth

罗氏、BMS发布2025年Q1财报

药械追踪No.1 / 康方生物依沃西单抗获批新适应证，一线治疗PD-L1阳性NSCLC2025年4月27日，康方生物宣布，旗下依沃西单抗注射液（商品名：依达方）已获得中国国家药品监督管理局（NMPA）批准新适应证，单药用于PD-L1阳性（TPS≥1%）的表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶（ALK）阴性的局部晚期或转移性非小细胞肺癌（NSCLC）的一线治疗。此次新适应证获批是基于III期AK112-303/HARMONi-2临床研究的积极成果。在ITT人群中，依沃西单抗对比帕博利珠单抗在改善无进展生存期方面具备优效性（mPFS：11.14个月 vs 5.82个月），将患者的疾病进展/死亡风险降低49%，且期中分析显示总生存获益显著（OS HR=0.777）。依沃西单抗是全球首个在头对头“药王”帕博利珠单抗的III期临床研究中获得显著阳性结果的药物。依达方（依沃西单抗注射液）是康方生物自主研发的、全球首创PD-1/VEGF双特异性肿瘤免疫治疗药物。依达方于2024年5月获国家药监局批准上市，用于EGFR-TKI治疗进展的局部晚期或转移性非鳞非小细胞肺癌，成为全球首个获批上市的“肿瘤免疫+抗血管生成“协同抗肿瘤机制的双特异性抗体新药；同年11月，依达方及该适应证被纳入2024年国家医保目录。->点击文末阅读原文，解锁完整双语新闻No.2 / 强生IL-23单抗特诺雅获欧盟批准用于溃疡性结肠炎患者2025年4月25日，强生（NYSE：JNJ）宣布，特诺雅/TREMFYA（古塞奇尤单抗注射液）已获欧盟委员会（EC）批准，用于治疗对常规疗法或生物制剂治疗应答不足、失去应答或不耐受的中重度活动性溃疡性结肠炎（UC）成人患者。此次批准主要基于QUASAR研究项目的积极数据。QUASAR包括一项IIb期诱导剂量探索研究和两项III期诱导及维持研究，结果显示，在第44周，接受每8周一次100毫克古塞奇尤单抗皮下（SC）维持治疗的患者有45%达到了临床缓解的主要终点，35%实现内镜缓解；接受每4周一次200毫克古塞奇尤单抗皮下维持治疗的患者有50%达到了临床缓解，34%达到内镜缓解；而安慰剂组分别仅有19%和15%的患者达到临床和内镜缓解。古塞奇尤单抗安全性与既往报道一致。古塞奇尤单抗是首个获得批准的全人源、具有双重作用机制的白介素23（IL-23）抑制剂。此前，古塞奇尤单抗于2017年11月在欧盟首次获批，用于适合全身治疗的成人中重度斑块状银屑病；2020年11月，获欧盟批准新增适应证，用于对既往疾病修饰抗风湿药物治疗应答不足或不耐受的活动性银屑病关节炎成人患者。->点击文末阅读原文，解锁完整双语新闻No.3 / 强生埃万妥单抗在华获批新适应证，用于EGFR TKI经治NSCLC2025年4月25日，强生宣布，锐珂（埃万妥单抗注射液）获得中国国家药品监督管理局（NMPA）批准新适应证，与卡铂和培美曲塞联合给药，适用于治疗携带表皮生长因子受体（EGFR）19号外显子缺失或21号外显子L858R置换突变且在EGFR酪氨酸激酶抑制剂治疗期间或之后疾病进展的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）成人患者。此次获批是基于III期MARIPOSA-2研究的积极数据。该研究表明，与单独化疗组相比，埃万妥单抗联合化疗可将疾病进展或死亡风险降低52%，显著改善患者中位无进展生存期（mPFS：6.3个月 vs 4.2个月）；亚洲人群PFS获益与全球一致（mPFS：10.3个月 vs 4.2个月）。埃万妥单抗是一款靶向EGFR和MET的双特异性抗体。2025年2月8日，埃万妥单抗获NMPA批准上市，与卡铂和培美曲塞联合给药，适用于经检测确认携带表皮生长因子受体（EGFR）20号外显子插入突变的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。->点击文末阅读原文，解锁完整双语新闻No.4 / 国内首个！辉瑞英利达肾癌一线靶免联合治疗在华获批上市2025年4月25日，辉瑞公司宣布，其口服靶向药英立达（Inlyta，通用名：阿昔替尼片）于2025年4月22日获国家药监局批准上市，联合特瑞普利单抗用于中高危的不可切除或转移性肾细胞癌（RCC）患者的一线治疗，这也是中国肾癌治疗领域首个且唯一获批的一线靶免联合治疗方案。英立达（阿昔替尼）是一种口服的、作用于血管内皮生长因子受体（VEGFR）1，2和3的强效和高选择性酪氨酸激酶抑制剂，抑制肿瘤生长、血管新生和肿瘤进展。此次一线适应证的获批是基于国内首个晚期肾癌靶免联合治疗的关键Ⅲ期临床RENOTORCH研究。->点击文末阅读原文，解锁完整双语新闻企业动态No.1 / 罗氏2025年Q1营收增长6%，中国药品销售额激增14%瑞士制药巨头罗氏集团（SWX: ROG）公布2025年第一季度财报，集团全球收入同比增长6%（按固定汇率计算，下同）至154.4亿瑞士法郎（约186.4亿美元）。其中，制药业务收入同比增长8%至119.5亿瑞士法郎（约144.3亿美元），诊断业务收入与去年同期持平，为34.9亿瑞士法郎（约42.1亿美元）。制药部门的核心增长动力包括：乳腺癌药物赫捷康（帕妥珠单抗/曲妥珠单抗/透明质酸酶复方制剂）、眼科药物罗视佳（法瑞西单抗）、过敏与哮喘疗法茁乐（奥马珠单抗）、血友病药物舒友立乐（艾美赛珠单抗）及流感药物速福达（玛巴洛沙韦）。上述药物合计贡献销售额36亿瑞士法郎（约43亿美元），较2024年同期增加7亿瑞士法郎（约8.45亿美元）。按地区来看，美国市场药品销售额同比增长6%至62.2亿瑞士法郎（约75亿美元），欧洲增长5%至23.2亿瑞士法郎（约28亿美元），日本增长3%至6.71亿瑞士法郎（约8.1亿美元），国际市场增长18%至27.3亿瑞士法郎（约33亿美元）。在国际市场中，中国市场受速福达和赫捷康的需求推动，贡献了14%的增速。->点击文末阅读原文，解锁完整双语新闻No.2 / BMS：2025第一季度收入下滑4%美跨国药企百时美施贵宝（BMS；NYSE: BMY）发布2025年第一季度财报显示，收入同比下降4%（按固定汇率计算，下同）至112亿美元。美国市场收入同比下降7%至79亿美元，国际市场收入则同比增长2%至33亿美元。营收下滑主要由于瑞复美（来那度胺）、Pomalyst（泊马度胺）、施达赛（达沙替尼）及凯素（注射用紫杉醇白蛋白结合型）等专利到期产品收入同比骤降20%。可喜的是，PD-1抑制剂欧狄沃（纳武利尤单抗）销售额同比增长12%至22.7亿美元。其他增长驱动力包括：靶向CD19 CAR-T疗法Breyanzi（利基迈仑赛）销售额同比增长148%至2.04亿美元；贫血疗法利布洛泽（罗特西普）同比增长36%至3.9亿美元；肥厚型心肌病（HCM）疗法迈凡妥（玛伐凯泰）同比暴涨90%至1.26亿美元。财报还提到了2024年9月获批的精神分裂症口服新药Cobenfy（呫诺美林，曲司氯铵）在美国市场的强劲上市表现。遗憾的是，BMS上周公布的III期数据显示，该药作为非典型抗精神病药物的辅助疗法未能达到主要终点，可能削弱其增长前景。BMS上调全年业绩指引：预计总收入将达458亿至468亿美元，较此前预测的455亿美元有所提升，这部分得益于约5亿美元的有利外汇影响。BMS还将其非GAAP每股收益（EPS）预期上调了0.15美元，至每股6.70美元至7.00美元之间。值得注意的是，该业绩指引未考虑目前关税政策的潜在影响。->点击文末阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I”自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作▶ xujingou@baidu.com数据库 | 咨询服务 | 资讯追踪▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

临床3期财报上市批准申请上市

100 项与玛伐凯泰相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14921

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
梗阻性肥厚型心肌病	美国	Bristol Myers Squibb Co.	2022-04-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
梗阻性肥厚型心肌病	申请上市	中国	上海联拓生物科技有限公司	2023-04-22
非梗阻性肥厚型心肌病	临床3期	日本	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	法国	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	奥地利	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	西班牙	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	挪威	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	波兰	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	比利时	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	荷兰	Bristol Myers Squibb Co.	2022-12-14
非梗阻性肥厚型心肌病	临床3期	捷克	Bristol Myers Squibb Co.	2022-12-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05582395 (ODYSSEY-HCM, Company_Website) 人工标引	临床3期	非梗阻性肥厚型心肌病	580	Camzyos	願糧壓鬱醖憲構鹽鑰艱(壓醖廠顧獵鹽範製艱襯) = did not meet 獵選憲窪鑰膚簾夢鹹衊 (顧顧觸觸積餘觸製繭膚 ) 未达到更多	不佳	2025-04-14
				Placebo
NCT04766892 (EMBARK-HFpEF, CTgov)	临床2期	射血分数保留型心力衰竭	30	Mavacamten	鹹蓋簾鬱廠壓簾夢範構(遞齋觸淵繭鬱構襯淵選) = 餘憲餘壓築選遞膚壓夢構鹹醖糧鹹蓋觸鬱網膚 (糧觸築鏇窪鏇獵鏇鬱築, 築齋鬱鏇衊構構夢糧顧 ~ 築膚夢網襯衊積窪鹹獵) 更多	-	2025-03-20
NCT03496168 (PIONEER-OLE, CTgov)	临床2期	梗阻性肥厚型心肌病	13	Mavacamtem (Mavacamtem)	(廠鹹鑰獵遞壓衊鏇積憲) = 遞夢觸簾網膚憲襯顧鹹淵繭廠淵築鏇繭淵艱繭 (獵選襯憲夢構淵鹽選蓋, 選夢齋構築構廠繭築蓋 ~ 齋鏇獵遞夢鑰願餘餘鹽) 更多	-	2025-01-09
				Mavacamten (Mavacamten)	繭顧選網鹹網顧糧範鬱(夢糧鏇積積遞餘壓醖醖) = 鏇構鑰築鑰糧鹽簾鏇窪觸築觸顧範鏇繭膚淵鹹 (壓顧糧構窪觸鑰齋衊憲, 鬱齋顧齋鹹遞顧夢顧鹹 ~ 餘顧繭範鬱繭膚築獵壓) 更多
NCT05414175 (HORIZON-HCM, CTgov)	临床3期	梗阻性肥厚型心肌病	38	Mavacamten	鏇選網簾窪艱膚選鹽齋(衊構鑰簾積鑰壓艱願糧) = 壓選願範簾簾醖構膚壓願醖蓋鬱齋鑰繭艱憲淵 (齋艱蓋鏇遞壓構築範鑰, 鏇製遞襯顧憲壓繭鹽網 ~ 築窪簾築觸構壓蓋齋醖) 更多	-	2024-12-04
NCT03470545 (EXPLORER-HCM, Pubmed \| J Card Fail)	临床3期	梗阻性肥厚型心肌病	-	mavacamten (Age ≤60 years)	襯窪醖觸蓋繭鹹鏇醖膚(壓構觸簾鏇網廠製願築) = 築鏇顧壓醖窪壓窪範築觸鏇齋範繭醖鹽夢衊鏇 (醖觸鏇衊構淵鏇齋繭選 ) 更多	积极	2024-12-01
				mavacamten (Age >60 years)	襯窪醖觸蓋繭鹹鏇醖膚(壓構觸簾鏇網廠製願築) = 遞齋簾鹽壓糧簾積積膚觸鏇齋範繭醖鹽夢衊鏇 (醖觸鏇衊構淵鏇齋繭選 ) 更多
NCT05174416 (CTgov)	临床3期	梗阻性肥厚型心肌病	81	Mavacamten (Mavacamten)	齋鏇獵鹹壓鑰簾鹽憲願(遞窪觸醖觸觸構蓋鹽遞) = 簾築築壓蓋構顧淵淵膚艱餘艱積鏇鹽鑰顧衊壓 (淵鏇窪廠簾鏇夢淵網簾, 壓鹹範鹽築鏇廠膚鬱繭 ~ 網膚壓壓鏇範鹹齋觸繭) 更多	-	2024-09-19
				Placebo (Placebo)	齋鏇獵鹹壓鑰簾鹽憲願(遞窪觸醖觸觸構蓋鹽遞) = 衊壓齋衊糧醖齋鬱窪壓艱餘艱積鏇鹽鑰顧衊壓 (淵鏇窪廠簾鏇夢淵網簾, 構膚壓壓選艱壓鬱壓醖 ~ 糧淵壓餘艱糧觸醖製夢) 更多
NCT03723655 (EXPLORER-LTE, BusinessWire) 人工标引	临床3期	梗阻性肥厚型心肌病	251	CAMZYOS® (mavacamten)	鑰醖鏇艱衊簾鏇蓋遞淵(鬱願顧遞鑰鹽範糧廠廠) = 觸糧壓鹹範鑰網遞襯膚遞淵襯壓積築壓夢衊膚 (鹽艱壓鏇鑰鹽憲製淵餘 ) 更多	积极	2024-09-01
NCT04349072 (Pubmed \| JACC Cardiovasc Imaging)	临床3期	梗阻性肥厚型心肌病	-	Mavacamten	構齋衊艱簾窪獵蓋選繭(襯夢膚膚構選獵獵製構) = 願簾築憲範襯積顧壓艱繭窪選積鬱廠齋蓋構遞 (壓遞願膚積窪餘願選鬱 ) 更多	-	2024-09-01
				Placebo	構齋衊艱簾窪獵蓋選繭(襯夢膚膚構選獵獵製構) = 網餘膚網餘艱鏇繭鑰簾繭窪選積鬱廠齋蓋構遞 (壓遞願膚積窪餘願選鬱 ) 更多
ESC2024	N/A	梗阻性肥厚型心肌病	-	Mavacamten 2.5 mg	(遞選範願構網廠齋艱膚) = 艱鏇糧顧壓襯衊衊窪齋淵糧鬱廠選觸鹹餘簾夢 (艱鏇窪範衊構鹽顧廠鏇 ) 更多	-	2024-08-31
				Mavacamten 5 mg	(遞選範願構網廠齋艱膚) = 築艱淵範願鹹糧網遞選淵糧鬱廠選觸鹹餘簾夢 (艱鏇窪範衊構鹽顧廠鏇 ) 更多
NCT05135871 (CTgov)	临床1期	肥大型心肌病	45	Mavacamten (Cohort 1: Mavacamten 15 mg)	壓鹹餘願顧鹹壓觸願鏇(獵範夢壓齋簾選構廠築) = 繭衊襯餘選壓衊衊築鬱齋鬱製衊選艱鹹艱鏇觸 (繭壓襯繭壓壓製窪顧鑰, 遞齋淵餘遞網繭齋鏇觸 ~ 醖鹹膚鹹鏇蓋醖積齋獵) 更多	-	2024-07-25
				Mavacamten (Cohort 2: Mavacamten 25 mg)	壓鹹餘願顧鹹壓觸願鏇(獵範夢壓齋簾選構廠築) = 簾獵觸鹹襯憲艱鹹餘壓齋鬱製衊選艱鹹艱鏇觸 (繭壓襯繭壓壓製窪顧鑰, 顧糧衊襯觸觸鬱簾壓鹽 ~ 選繭積衊觸網夢觸簾廠) 更多